sie ist gestartet-orthovita -914566 - 500 Beiträge pro Seite

[jacky06]

habe es euch vor 2 wochen vorhergesagt,und geht weiter.

[a.l.e.x.]

Hallo zusammen,

lohnt sich hier noch eun Investment? Rege gehandelt wird die Aktie ja nicht hier.
Bitte um einen Tipp.

Gruß

[a.l.e.x.]

Orthovita upgraded to "buy"

Friday, February 13, 2004 10:09:08 AM ET
First Albany

NEW YORK, February 13 (New Ratings) - Analysts at First Albany upgrade Orthovita (VITA) from "neutral" to "buy." The target price has been raised from $3.65 to $8.00.

[a.l.e.x.]

Orthovita initiated with "buy"

Friday, March 05, 2004 7:13:06 AM ET
WR Hambrecht & Co

NEW YORK, March 5 (New Ratings) - Analyst David Turkaly of WR Hambrecht initiates coverage of Orthovita Inc (VITA) with a "buy" rating. The 12-month target price is set to $5.50.

Shares of Orthovita Inc, a leading developer of synthetic biomaterials, are currently trading at $3.65.

According to WR Hambrecht `s research note published this morning, the company develops synthetic bone replacements, which caters to a wide market in the orthopedic sector. Vitoss accounts for more than 95% of the company`s sales, the analyst states. The company has two other products, Cortoss and Rhakoss, which are still in the testing phases, the analyst mentions. Cortoss, which is likely to be approved in the US by 2008, has robust potential in the vertebral compression fracture (VCF) market.

According to WR Hambrecht, Orthovita is currently using a hybrid sales strategy to market its products. The company intends to increase its market base through direct selling initiatives during 1H04, the analysts state. The company is also expected to launch devices based on the Vitoss platform to boost its revenues in the near future. The company expects to post profits only in 2H05 due to the expenses related to the clinical trials and the expansion of its sales force, the analysts mention.

The EPS estimates for 2004, 2005 and 2006 are -$0.19, -$0.11 and $0.03, respectively.

WR Hambrecht initiates coverage of Orthovita Inc with a "buy" rating.

© 2004 New Ratings

[jacky06]

ja ja,habe es euch mitte januar gesagt als es los ging und der hammer kommt noch am 05.05. zur pressekonferenz.


Orthovita Schedules First Quarter 2004 Financial Results Conference Call

MALVERN, Pa., Apr 22, 2004 (BUSINESS WIRE) -- Orthovita, Inc. (NASDAQ NM:VITA), a leading developer of orthopaedic biomaterials, will hold a conference call on Wednesday, May 5, 2004, at 8:30 a.m. EST to review and discuss its financial results for the first quarter of 2004. Antony Koblish, President and Chief Executive Officer, and Joseph M. Paiva, Chief Financial Officer of Orthovita, will host the call.

The phone number to join the conference call from within the U.S. is [phone], and from outside the U.S. is [phone]. The conference identification number is 6986217. Participants should dial in five to ten minutes prior to the scheduled start time for the conference call.

A replay of the conference call will be available for one week beginning May 5, 2004, at 9:30 a.m. EST, and ending May 12, 2004, at 11:59 p.m. EST. To access the replay, please dial [phone] within the U.S. or [phone] from outside the U.S. The replay identification number is 6986217